BTIG Research Reaffirms “Buy” Rating for Monopar Therapeutics (NASDAQ:MNPR)

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating reaffirmed by investment analysts at BTIG Research in a report released on Monday,Benzinga reports. They currently have a $104.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 72.24% from the stock’s current price.

MNPR has been the subject of a number of other reports. Raymond James Financial cut shares of Monopar Therapeutics from a “strong-buy” rating to an “outperform” rating and lowered their price target for the company from $142.00 to $123.00 in a research report on Friday, November 14th. Barclays set a $125.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a report on Monday, October 13th. Leerink Partners assumed coverage on Monopar Therapeutics in a research note on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company. Morgan Stanley started coverage on Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $60.38 on Monday. Monopar Therapeutics has a 1 year low of $26.06 and a 1 year high of $105.00. The stock has a market capitalization of $403.34 million, a PE ratio of -17.55 and a beta of 1.52. The business’s 50-day moving average is $71.94 and its 200 day moving average is $65.79.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). As a group, equities research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In other news, CFO Quan Anh Vu acquired 1,500 shares of the firm’s stock in a transaction dated Friday, December 26th. The shares were acquired at an average cost of $69.95 per share, with a total value of $104,925.00. Following the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors have recently modified their holdings of MNPR. Russell Investments Group Ltd. bought a new position in shares of Monopar Therapeutics during the third quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics in the second quarter worth $34,000. BNP Paribas Financial Markets lifted its position in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the last quarter. AlphaQuest LLC boosted its stake in shares of Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after purchasing an additional 569 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the last quarter. 1.83% of the stock is owned by institutional investors.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.